

> d his

(FILE 'HOME' ENTERED AT 09:35:28 ON 24 AUG 2006)

FILE 'REGISTRY' ENTERED AT 09:35:48 ON 24 AUG 2006

L1 STRUC
L2 50 S L1
L3 18324 S L1 FUL
L4 2850 S L3 AND (PIPERIDIN? OR AZEPIDIN?)
E AZEPIDIN
L5 74 S L3 AND AZEPIN?

FILE 'CAPLUS' ENTERED AT 09:38:59 ON 24 AUG 2006

L6 16 S L5

FILE 'REGISTRY' ENTERED AT 09:40:41 ON 24 AUG 2006

FILE 'CAPLUS' ENTERED AT 09:42:12 ON 24 AUG 2006

FILE 'STNGUIDE' ENTERED AT 09:48:08 ON 24 AUG 2006

FILE 'CAPLUS' ENTERED AT 09:49:53 ON 24 AUG 2006

FILE 'REGISTRY' ENTERED AT 09:50:50 ON 24 AUG 2006

L7 2850 S L4 NOT L5
L8 STRUC
L9 546 SEARCH L8 SSS SUB=L7 FUL
L10 546 SEARCH L8 SSS SUB=L9 FUL

FILE 'CAPLUS' ENTERED AT 09:57:41 ON 24 AUG 2006

L11 2 S L10

FILE 'STNGUIDE' ENTERED AT 09:59:22 ON 24 AUG 2006

FILE 'REGISTRY' ENTERED AT 10:06:36 ON 24 AUG 2006

L12 2304 S L7 NOT L10

FILE 'CAPLUS' ENTERED AT 10:08:33 ON 24 AUG 2006

L13 159 S L12
L14 3 S L13 AND LIPASE
L15 1 S L13 AND PHOSPHOLIPASE

=> s l14 not l15

L16 3 L14 NOT L15

=> s l13 and (phospho?(l)lipase)

1072064 PHOSPHO?

47325 LIPASE

3940 PHOSPHO?(L)LIPASE

L17 0 L13 AND (PHOSPHO?(L)LIPASE)

=> d bib hitstr l14 1-3

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:60473 CAPLUS

DN 140:128423

TI Preparation of heterocyclylbenzoylureas for treating type 2 diabetes

IN Schoenafinger, Karl; Defossa, Elisabeth; Kadereit, Dieter; Von Roedern, Erich; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas; Wendt, Karl-Ulrich

PA Aventis Pharma Deutschland GmbH, Germany

SO PCT Int. Appl., 67 pp.


CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004007455	A1	20040122	WO 2003-EP7078	20030703
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10231627	A1	20040205	DE 2002-10231627	20020712
	DE 10231627	B4	20060309		
	DE 10306503	A1	20040826	DE 2003-10306503	20030217
	DE 10320326	A1	20041202	DE 2003-10320326	20030506
	CA 2493374	AA	20040122	CA 2003-2493374	20030703
	AU 2003249937	A1	20040202	AU 2003-249937	20030703
	EP 1523475	A1	20050420	EP 2003-763692	20030703
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003012697	A	20050426	BR 2003-12697	20030703
	CN 1668593	A	20050914	CN 2003-816581	20030703
	JP 2006502247	T2	20060119	JP 2005-505058	20030703
	US 2004152743	A1	20040805	US 2003-617498	20030711
	ZA 2004010133	A	20051123	ZA 2004-10133	20041215
	NO 2005000648	A	20050207	NO 2005-648	20050207
PRAI	DE 2002-10231627	A	20020712		
	DE 2003-10306503	A	20030217		
	DE 2003-10320326	A	20030506		
	US 2002-430782P	P	20021204		
	WO 2003-EP7078	W	20030703		
OS	MARPAT 140:128423				
IT	648917-24-2P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)				
RN	648917-24-2 CAPLUS				
CN	4-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)				



IT 648917-12-8P 648917-13-9P 648917-14-0P
 648917-15-1P 648917-16-2P 648917-17-3P
 648917-18-4P 648917-19-5P 648917-20-8P
 648917-21-9P 648917-22-0P 648917-23-1P
 648917-25-3P 648917-26-4P 648917-27-5P


648917-28-6P 648917-29-7P 648917-30-0P
 648917-31-1P 648917-32-2P 648917-33-3P
 648917-34-4P 648917-35-5P 648917-36-6P
 648917-37-7P 648917-38-8P 648917-39-9P
 648917-40-2P 648917-42-4P 648917-43-5P
 648917-44-6P 648917-45-7P 648917-46-8P
 648917-47-9P 648917-48-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)


RN 648917-12-8 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[[[(2-chloro-4,5-
 difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI) (CA INDEX
 NAME)




RN 648917-13-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-
 difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI) (CA INDEX
 NAME)




RN 648917-14-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-
 difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, monosodium salt
 (9CI) (CA INDEX NAME)




RN 648917-15-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 648917-16-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 648917-17-3 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 648917-18-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 648917-19-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 648917-20-8 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-5-methylphenyl]- (9CI) (CA INDEX NAME)




RN 648917-21-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-5-methylphenyl]- (9CI) (CA INDEX NAME)




RN 648917-22-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 648917-23-1 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 648917-25-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 648917-26-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 648917-27-5 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-chloro-2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 648917-28-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-(methoxycarbonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 648917-29-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-(methoxycarbonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 648917-30-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 648917-31-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 648917-32-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, methyl ester (9CI)
(CA INDEX NAME)




RN 648917-33-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, methyl ester (9CI)
(CA INDEX NAME)




RN 648917-34-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-(methoxycarbonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 648917-35-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-(methoxycarbonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 648917-36-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 648917-37-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-(methanesulfonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 648917-38-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-4-(methylsulfonyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 648917-39-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-carboxy-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 648917-40-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[4-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-6-fluoro[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



RN 648917-42-4 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-5-fluorophenyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 648917-43-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 648917-44-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 648917-45-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-4-fluorophenyl]-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 648917-13-9

CMF C20 H17 Cl F3 N3 O4




CM 2


CRN 77-86-1
CMF C4 H11 N O3




RN 648917-46-8 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[2-[[[(2-chloro-4,5-difluorobenzoyl) amino] carbonyl] amino]-4-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 648917-47-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[4-[[[(2-chloro-4,5-difluorobenzoyl) amino] carbonyl] amino]-6-fluoro[1,1'-biphenyl]-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 648917-48-0 CAPLUS
CN 4-Piperidinecarboxamide, 1-[4-[[[(2-chloro-4,5-difluorobenzoyl) amino] carbonyl] amino]-6-fluoro[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:696732 CAPLUS
DN 139:214471
TI Preparation of 5-alkoxy-3-phenyl-1,3,4-oxadiazol-2(3H)-ones for producing medicaments inhibiting pancreatic lipase
IN Schoenafinger, Karl; Petry, Stefan; Mueller, Guenter; Bauer, Armin; Heuer, Hubert Otto
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003072098	A1	20030904	WO 2003-EP1560	20030217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10208986	A1	20030911	DE 2002-10208986	20020228
CA 2477005	AA	20030904	CA 2003-2477005	20030217
AU 2003210292	A1	20030909	AU 2003-210292	20030217
EP 1482929	A1	20041208	EP 2003-742942	20030217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008045	A	20041221	BR 2003-8045	20030217
JP 2005519079	T2	20050630	JP 2003-570844	20030217
CN 1638766	A	20050713	CN 2003-804767	20030217
US 2003236288	A1	20031225	US 2003-376579	20030228
NO 2004004091	A	20040927	NO 2004-4091	20040927
PRAI DE 2002-10208986	A	20020228		
US 2002-365704P	P	20020319		
WO 2003-EP1560	W	20030217		
OS MARPAT 139:214471				
IT 359848-89-8P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of (alkoxy)(phenyl)oxadiazolones for producing medicaments inhibiting pancreatic lipase)				
RN 359848-89-8 CAPLUS				
CN Urea, N-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2-methylphenyl]-N'-				

[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:676756 CAPLUS

DN 135:242234

TI Preparation of 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones as
hormone-sensitive lipase inhibitors

IN Schoenafinger, Karl; Petry, Stefan; Mueller, Guenter; Baringhaus,
Karl-Heinz

PA Aventis Pharma Deutschland G.m.b.H., Germany

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066531	A1	20010913	WO 2001-EP1898	20010220
	WO 2001066531	C1	20020725		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 10010968	A1	20010913	DE 2000-10010968	20000307
	DE 10102265	C1	20020808	DE 2001-10102265	20010118
	CA 2401953	AA	20010913	CA 2001-2401953	20010220
	EP 1263745	A1	20021211	EP 2001-905805	20010220
	EP 1263745	B1	20040519		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001008974	A	20030603	BR 2001-8974	20010220
	JP 2003525931	T2	20030902	JP 2001-565347	20010220
	EE 200200498	A	20040216	EE 2002-498	20010220
	AT 267184	E	20040615	AT 2001-905805	20010220
	NZ 521207	A	20050429	NZ 2001-521207	20010220
	AU 784827	B2	20060629	AU 2001-33787	20010220
	RU 2281283	C2	20060810	RU 2002-126556	20010220
	NO 2002004201	A	20020903	NO 2002-4201	20020903
PRAI	DE 2000-10010968	A	20000307		
	DE 2001-10102265	A	20010118		
	WO 2001-EP1898	W	20010220		
OS	MARPAT 135:242234				
IT	359848-89-8P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones as
hormone-sensitive lipase inhibitors)

RN 359848-89-8 CAPLUS

CN Urea, N-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2-methylphenyl]-N'-
[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

d his

(FILE 'HOME' ENTERED AT 09:35:28 ON 24 AUG 2006)

FILE 'REGISTRY' ENTERED AT 09:35:48 ON 24 AUG 2006

L1 STRUC
L2 50 S L1
L3 18324 S L1 FUL
L4 2850 S L3 AND (PIPERIDIN? OR AZEPIDIN?)
E AZEPIDIN
L5 74 S L3 AND AZEPIN?

FILE 'CAPLUS' ENTERED AT 09:38:59 ON 24 AUG 2006

L6 16 S L5

FILE 'REGISTRY' ENTERED AT 09:40:41 ON 24 AUG 2006

FILE 'CAPLUS' ENTERED AT 09:42:12 ON 24 AUG 2006

FILE 'STNGUIDE' ENTERED AT 09:48:08 ON 24 AUG 2006

FILE 'CAPLUS' ENTERED AT 09:49:53 ON 24 AUG 2006

FILE 'REGISTRY' ENTERED AT 09:50:50 ON 24 AUG 2006

L7 2850 S L4 NOT L5
L8 STRUC
L9 546 SEARCH L8 SSS SUB=L7 FUL
L10 546 SEARCH L8 SSS SUB=L9 FUL

FILE 'CAPLUS' ENTERED AT 09:57:41 ON 24 AUG 2006

L11 2 S L10

FILE 'STNGUIDE' ENTERED AT 09:59:22 ON 24 AUG 2006

FILE 'REGISTRY' ENTERED AT 10:06:36 ON 24 AUG 2006

L12 2304 S L7 NOT L10

FILE 'CAPLUS' ENTERED AT 10:08:33 ON 24 AUG 2006

L13 159 S L12
L14 3 S L13 AND LIPASE

=> s l13 and phospholipase

44488 PHOSPHOLIPASE

L15 1 L13 AND PHOSPHOLIPASE

=> d bib

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:878375 CAPLUS

DN 141:350047

TI Preparation of phospholipase C inhibitors for use in treating
inflammatory diseases

IN Lagu, Bharat; Rupert, Kenneth; Wachter, Michael

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089901	A2	20041021	WO 2004-US9847	20040331
	WO 2004089901	A3	20041209		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004242639 A1 20041202 US 2004-814070 20040331
 PRAI US 2003-459078P P 20030331
 OS MARPAT 141:350047

=> d bib abs hitstr

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:878375 CAPLUS

DN 141:350047

TI Preparation of phospholipase C inhibitors for use in treating inflammatory diseases

IN Lagu, Bharat; Rupert, Kenneth; Wachter, Michael

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089901	A2	20041021	WO 2004-US9847	20040331
	WO 2004089901	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2004242639 A1 20041202 US 2004-814070 20040331
 PRAI US 2003-459078P P 20030331
 OS MARPAT 141:350047
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention is directed to heterocyclyl-substituted anilino phospholipase C inhibitor compds. I [X = (un)substituted-amino, -heterocyclyl, etc.; R3 = O or S; R4 = cycloalkyl, benzofused dioxolyl, benzofused dioxinyl, or aryl; L = a bond or a linking group; R5 = (un)substituted-alkyl, -cycloalkyl, or -aryl; Y = (un)substituted-alkyl; n = 1-2] useful in treating or ameliorating an inflammatory disorders and/or restenosis and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. For example, compound II were prepared in a multi-steps employing a solid phase synthesis starting from 4-fluoro-3-nitrobenzoic acid. The latter inhibits phospholipase C- β 2 with an IC50

= 3.4 μ M.


IT 775349-73-0P 775349-74-1P 775349-75-2P
775349-76-3P 775349-77-4P 775349-78-5P
775349-79-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ureido piperidinyl derivative as phospholipase c inhibitors for treatment of inflammatory disorders)


RN 775349-73-0 CAPLUS

CN Benzamide, 3-[[[(phenylamino)carbonyl]amino]-4-[4-(phenylmethyl)-1-piperidinyl]]- (9CI) (CA INDEX NAME)




RN 775349-74-1 CAPLUS

CN Benzamide, 3-[[[(phenylamino)carbonyl]amino]-4-(4-phenyl-1-piperidinyl)]- (9CI) (CA INDEX NAME)




RN 775349-75-2 CAPLUS

CN Benzamide, 3-[[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]-4-(4-phenyl-1-piperidinyl)]- (9CI) (CA INDEX NAME)




RN 775349-76-3 CAPLUS

CN Piperazine, 1-[4-(4,4-diphenyl-1-piperidinyl)-3-[[[(phenylamino)carbonyl]amino]benzoyl]]- (9CI) (CA INDEX NAME)




RN 775349-77-4 CAPLUS

CN Hydrazinecarboxamide, N-[5-(aminocarbonyl)-2-[4-(phenylmethyl)-1-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 775349-78-5 CAPLUS

CN Benzamide, 4-[4-(diphenylmethyl)-1-piperidinyl]-3-[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 775349-79-6 CAPLUS

CN Piperazine, 1-[4-[4-(diphenylmethylene)-1-piperidinyl]-3-[[(phenylamino)carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



```
=> d 11
L1 HAS NO ANSWERS
L1 STR
```



```
VAR G1=O/S
VPA 11-3/4/5 U
NODE ATTRIBUTES:
NSPEC IS R AT 11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RSPEC 4
NUMBER OF NODES IS 11
```

```
STEREO ATTRIBUTES: NONE
```

```
=> d his
```

```
(FILE 'HOME' ENTERED AT 09:35:28 ON 24 AUG 2006)
```

```
FILE 'REGISTRY' ENTERED AT 09:35:48 ON 24 AUG 2006
```

```
L1 STRUC
L2 50 S L1
L3 18324 S L1 FUL
L4 2850 S L3 AND (PIPERIDIN? OR AZEPIDIN?)
E AZEPIDIN
L5 74 S L3 AND AZEPIN?
```

```
FILE 'CAPLUS' ENTERED AT 09:38:59 ON 24 AUG 2006
```

```
L6 16 S L5
```

```
FILE 'REGISTRY' ENTERED AT 09:40:41 ON 24 AUG 2006
```

```
FILE 'CAPLUS' ENTERED AT 09:42:12 ON 24 AUG 2006
```

```
FILE 'STNGUIDE' ENTERED AT 09:48:08 ON 24 AUG 2006
```

```
FILE 'CAPLUS' ENTERED AT 09:49:53 ON 24 AUG 2006
```


```
FILE 'REGISTRY' ENTERED AT 09:50:50 ON 24 AUG 2006
```

```
L7 2850 S L4 NOT L5
L8 STRUC
L9 546 SEARCH L8 SSS SUB=L7 FUL
```

```
=> d 18
L8 HAS NO ANSWERS
```

L8

STR



VAR G1=O/S
 VPA 1-12/14/16 U
 VPA 23-13/15 U
 VPA 5-18/20/22 U
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 22 11
 NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

=> search l8

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
 ENTER SUBSET L# OR (END):19
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
 FULL SUBSET SEARCH INITIATED 09:57:34 FILE 'REGISTRY'
 FULL SUBSET SCREEN SEARCH COMPLETED - 546 TO ITERATE

100.0% PROCESSED 546 ITERATIONS 546 ANSWERS
 SEARCH TIME: 00.00.01

L10 546 SEA SUB=L9 SSS FUL L8

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	212.64	467.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

FILE 'CAPLUS' ENTERED AT 09:57:41 ON 24 AUG 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 110

L11 2 L10

=> d bib abs 1-2

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:878375 CAPLUS

DN 141:350047

TI Preparation of phospholipase C inhibitors for use in treating inflammatory diseases

IN Lagu, Bharat; Rupert, Kenneth; Wachter, Michael

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089901	A2	20041021	WO 2004-US9847	20040331
	WO 2004089901	A3	20041209		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004242639	A1	20041202	US 2004-814070	20040331
PRAI	US 2003-459078P	P	20030331		
OS	MARPAT 141:350047				
GI					


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention is directed to heterocyclyl-substituted anilino phospholipase C inhibitor compds. I [X = (un)substituted-amino, -heterocyclyl, etc.; R3 = O or S; R4 = cycloalkyl, benzofused dioxolyl, benzofused dioxinyl, or aryl; L = a bond or a linking group; R5 = (un)substituted-alkyl, -cycloalkyl, or -aryl; Y = (un)substituted-alkyl; n = 1-2] useful in treating or ameliorating an inflammatory disorders and/or restenosis and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. For example, compound II were prepared in a multi-steps

employing a solid phase synthesis starting from 4-fluoro-3-nitrobenzoic acid. The latter inhibits phospholipase C- β 2 with an IC50 = 3.4 μ M.

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:60473 CAPLUS
 DN 140:128423
 TI Preparation of heterocyclylbenzoylureas for treating type 2 diabetes
 IN Schoenafinger, Karl; Defossa, Elisabeth; Kadereit, Dieter; Von Roedern, Erich; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas; Wendt, Karl-Ulrich
 PA Aventis Pharma Deutschland GmbH, Germany
 SO PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004007455	A1	20040122	WO 2003-EP7078	20030703
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10231627	A1	20040205	DE 2002-10231627	20020712
	DE 10231627	B4	20060309		
	DE 10306503	A1	20040826	DE 2003-10306503	20030217
	DE 10320326	A1	20041202	DE 2003-10320326	20030506
	CA 2493374	AA	20040122	CA 2003-2493374	20030703
	AU 2003249937	A1	20040202	AU 2003-249937	20030703
	EP 1523475	A1	20050420	EP 2003-763692	20030703
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003012697	A	20050426	BR 2003-12697	20030703
	CN 1668593	A	20050914	CN 2003-816581	20030703
	JP 2006502247	T2	20060119	JP 2005-505058	20030703
	US 2004152743	A1	20040805	US 2003-617498	20030711
	ZA 2004010133	A	20051123	ZA 2004-10133	20041215
	NO 2005000648	A	20050207	NO 2005-648	20050207
PRAI	DE 2002-10231627	A	20020712		
	DE 2003-10306503	A	20030217		
	DE 2003-10320326	A	20030506		
	US 2002-430782P	P	20021204		
	WO 2003-EP7078	W	20030703		
OS	MARPAT 140:128423				
GI					



AB Title compds. [I; R1, R2 = H, (substituted) A, OA, COA, CO2A, AlkCO2H, AlkCO2A; A = alkyl; Alk = alkylene; R3, R4 = F, Cl, Br, OH, NO2, CN, (substituted) A, OA, alkenyloxy, alkynyl; R5 = H, F, Cl, Br, OH, NO2, CN, (substituted) A, OA, COA, AlkCO2H, AlkCO2A, SO2A, alkenyloxy, alkynyl; X = H, F, Cl, Br, OH, NO2, CN, (substituted) A, COA, AlkCO2H, AlkCO2A, SO2A, alkenyl, alkynyl, OA, SO1-2A, NHA, NA2, CO2H, CO2A, CONH2, CONHA, CONA2, SO2NH2, SO2NHA, SO2NA2, NHCOR6; R6 = H, A, cycloalkyl, cycloalkylalkylene, alkenyl, alkynyl, AlkCO2A, AlkCOA, AlkCO2H, AlkCONH2, aryl, Alkaryl, heteroaryl, Alkheteroaryl, heteroarylcarbonyl; het = 4-7 membered (substituted) heterocyclyl, with the exception of pyrrole; m = 1-5; n, p = 0-3], were prepared Thus, 1-(4-amino-3-fluorophenyl)-1H-[1,2,4]triazole (preparation given) and 2-chloro-4,5-difluorobenzoylisocyanate were stirred 30 min in MeCN to give 1-(2-chloro-4,5-difluorobenzoyl)-3-(2-fluor-4-[1,2,4]triazol-1-ylphenyl)urea. The latter at 10 μ M gave 94% inhibition of activated glycogen phosphorylase.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 2

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN


IT 648917-41-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclylbenzoylureas for treating type 2 diabetes)

RN 648917-41-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-carboxy-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]-, 4-methyl ester (9CI) (CA INDEX NAME)



=> d l1
 L1 HAS NO ANSWERS
 L1 STR



VAR G1=O/S
 VPA 11-3/4/5 U
 NODE ATTRIBUTES:
 NSPEC IS R AT 11
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 4
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

=> d his l3

(FILE 'REGISTRY' ENTERED AT 09:35:48 ON 24 AUG 2006)
 L3 18324 S L1 FUL

=> d his l5

(FILE 'REGISTRY' ENTERED AT 09:35:48 ON 24 AUG 2006)
 E AZEPIDIN
 L5 74 S L3 AND AZEPIN?

=> s 15

L6 16 L5

=> d bib 1-16

L6 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:164439 CAPLUS

DN 144:253908

TI Preparation of aryl urea derivatives as CB1 cannabinoid receptor modulators

IN Bloxham, Jason; Fyfe, Matthew Colin Thor; Horswill, James; Jeevaratnam, Revathy Perpetua; Keily, John; Procter, Martin James; Schofield, Karen Lesley; Shaaban, Salam; Swain, Simon Andrew; Wong-Kai-In, Philippe

PA Prosidion Limited, UK

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006018662	A2	20060223	WO 2005-GB50131	20050816
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-602268P P 20040816

OS MARPAT 144:253908

L6 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1242631 CAPLUS

DN 144:6677

TI Preparation of urea containing N-aryl or N-heteroaryl substituted heterocycles as antagonists of P2Y1 receptor for treating thrombotic conditions

IN Tuerdi, Huji; Chao, Hannguang J.; Qiao, Jennifer X.; Wang, Tammy C.; Gungor, Timur

PA USA

SO U.S. Pat. Appl. Publ., 102 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005261244	A1	20051124	US 2005-126567	20050510
	WO 2005113511	A1	20051201	WO 2005-US16422	20050511
	WO 2005113511	C2	20060202		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,				

SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 WO 2005113537 A2 20051201 WO 2005-US16525 20050511
 WO 2005113537 A3 20051222
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 PRAI US 2004-570288P P 20040512
 US 2005-665735P P 20050328
 US 2005-665817P P 20050328
 US 2005-126567 A 20050510
 OS MARPAT 144:6677
 L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:891946 CAPLUS
 DN 139:381494
 TI Preparation of semicarbazides as inhibitors of blood-coagulation factor Xa
 and VIIa
 IN Mederski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Dorsch, Dieter;
 Barnes, Christopher; Gleitz, Johannes
 PA Merck Patent Gmbh, Germany
 SO Ger. Offen., 18 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10220048	A1	20031113	DE 2002-10220048	20020504
	CA 2485065	AA	20031113	CA 2003-2485065	20030407
	WO 2003093254	A1	20031113	WO 2003-EP3581	20030407
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003227569	A1	20031117	AU 2003-227569	20030407
	EP 1501814	A1	20050202	EP 2003-724967	20030407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005171102	A1	20050804	US 2003-513451	20030407
	JP 2005530754	T2	20051013	JP 2004-501393	20030407
PRAI	DE 2002-10220048	A	20020504		

WO 2003-EP3581 W 20030407
OS MARPAT 139:381494

L6 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:154238 CAPLUS
DN 138:204941
TI Preparation of indol-5-ylureas and relate compounds for the treatment of obesity and type II diabetes
IN Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003015769	A1	20030227	WO 2002-EP8686	20020803
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10139416	A1	20030306	DE 2001-10139416	20010817
	CA 2457037	AA	20030227	CA 2002-2457037	20020803
	EP 1418906	A1	20040519	EP 2002-774498	20020803
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002011989	A	20040928	BR 2002-11989	20020803
	CN 1555260	A	20041215	CN 2002-818162	20020803
	JP 2005505530	T2	20050224	JP 2003-520728	20020803
	US 2003212070	A1	20031113	US 2002-218034	20020814
	EE 200400055	A	20040415	EE 2004-55	20030803
	NO 2004000678	A	20040513	NO 2004-678	20040216
	ZA 2004001221	A	20041027	ZA 2004-1221	20040216
	US 2004192693	A1	20040930	US 2004-820706	20040409
	US 2004198731	A1	20041007	US 2004-820703	20040409
	US 2004198732	A1	20041007	US 2004-820736	20040409
	US 2004198733	A1	20041007	US 2004-820883	20040409
PRAI	DE 2001-10139416	A	20010817		
	WO 2002-EP8686	W	20020803		
	US 2002-218034	A3	20020814		

OS MARPAT 138:204941

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:676565 CAPLUS
DN 135:247001
TI Oxidation dyeing composition for keratinous fibers and dyeing method using same
IN Lang, Gerard
PA L'Oreal, Fr.
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066072	A1	20010913	WO 2001-FR663	20010306
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2805738	A1	20010907	FR 2000-2858	20000306
	FR 2805738	B1	20030314		
	CA 2373099	AA	20010913	CA 2001-2373099	20010306
	EP 1181004	A1	20020227	EP 2001-913934	20010306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2001005561	A	20020319	BR 2001-5561	20010306
	AU 752948	B2	20021003	AU 2001-39341	20010306
	JP 2003525889	T2	20030902	JP 2001-564725	20010306
	ZA 2001008983	A	20020911	ZA 2001-8983	20011031
	US 2003028977	A1	20030213	US 2002-959702	20020503
PRAI	FR 2000-2858	A	20000306		
	WO 2001-FR663	W	20010306		
OS	MARPAT 135:247001				

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:676564 CAPLUS
DN 135:247000
TI Oxidation dyeing composition for keratinous fibers comprising
paraphenylenediamine derivatives and coupling agents
IN Lang, Gerard
PA L'Oreal, Fr.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066071	A1	20010913	WO 2001-FR660	20010306
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2805737	A1	20010907	FR 2000-2857	20000306
	FR 2805737	B1	20030103		
	CA 2373097	AA	20010913	CA 2001-2373097	20010306
	EP 1181005	A1	20020227	EP 2001-915449	20010306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2001005562	A	20020319	BR 2001-5562	20010306
	JP 2003525888	T2	20030902	JP 2001-564724	20010306

ZA 2001009069	A	20020613	ZA 2001-9069	20011102
US 2003009835	A1	20030116	US 2002-959704	20020208
US 6890362	B2	20050510		
PRAI FR 2000-2857	A	20000306		
WO 2001-FR660	W	20010306		

OS MARPAT 135:247000

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:676563 CAPLUS
DN 135:246999
TI Oxidation dyeing composition for keratinous fibers containing
paraphenylenediamine derivatives and oxidants
IN Lang, Gerard
PA L'Oreal, Fr.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066070	A1	20010913	WO 2001-FR646	20010305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2805739	A1	20010907	FR 2000-2860	20000306
	FR 2805739	B1	20030110		
	CA 2400464	AA	20010913	CA 2001-2400464	20010305
	EP 1263399	A1	20021211	EP 2001-911848	20010305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009175	A	20030422	BR 2001-9175	20010305
	JP 2003525887	T2	20030902	JP 2001-564723	20010305
	US 2003167579	A1	20030911	US 2003-333664	20030410
PRAI	FR 2000-2860	A	20000306		
	WO 2001-FR646	W	20010305		

OS MARPAT 135:246999

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:676562 CAPLUS
DN 135:246998
TI Oxidation dyeing composition for keratinous fibers comprising substituted
paraphenylenediamine derivatives and polymers
IN Lang, Gerard
PA L'Oreal, Fr.
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI WO 2001066069 A1 20010913 WO 2001-FR645 20010305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
FR 2805740 A1 20010907 FR 2000-2861 20000306
FR 2805740 B1 20030905
CA 2400459 AA 20010913 CA 2001-2400459 20010305
EP 1263398 A1 20021211 EP 2001-911847 20010305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2001009179 A 20030422 BR 2001-9179 20010305
JP 2003528054 T2 20030924 JP 2001-564722 20010305
US 2004088798 A1 20040513 US 2003-363147 20030911
PRAI FR 2000-2861 A 20000306
WO 2001-FR645 W 20010305
OS MARPAT 135:246998
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:676561 CAPLUS
DN 135:246997
TI Oxidation dyeing composition for keratinous fibers with a particular
paraphenylenediamine derivative and a particular direct dyeing agent
IN Lang, Gerard
PA L'Oreal, Fr.
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001066068	A1	20010913	WO 2001-FR644	20010305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2805741	A1	20010907	FR 2000-2862	20000306
FR 2805741	B1	20030620		
CA 2400456	AA	20010913	CA 2001-2400456	20010305
BR 2001009021	A	20021126	BR 2001-9021	20010305
EP 1263397	A1	20021211	EP 2001-911846	20010305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003528053	T2	20030924	JP 2001-564721	20010305
US 2003159221	A1	20030828	US 2003-333663	20030410
PRAI FR 2000-2862	A	20000306		
WO 2001-FR644	W	20010305		
OS MARPAT 135:246997				
RE.CNT 7				

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:646000 CAPLUS
 DN 133:222725
 TI Preparation of thiazolylureas as antivirals
 IN Fischer, Rudiger; Kleymann, Gerald; Baumeister, Judith; Bender, Wolfgang;
 Betz, Ulrich; Eckenberg, Peter; Handke, Gabriele; Hendrix, Martin;
 Schneider, Udo; Weber, Olaf; Henninger, Kerstin; Jensen, Axel; Keldenich,
 Jorg
 PA Bayer Aktiengesellschaft, Germany
 SO PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000053591	A1	20000914	WO 2000-EP1498	20000224
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19959958	A1	20010830	DE 1999-19959958	19991213
	CA 2366607	AA	20000914	CA 2000-2366607	20000224
	EP 1161423	A1	20011212	EP 2000-907614	20000224
	EP 1161423	B1	20041110		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539119	T2	20021119	JP 2000-604030	20000224
	ES 2232427	T3	20050601	ES 2000-907614	20000224
	US 6500817	B1	20021231	US 2001-914554	20010831
PRAI	DE 1999-19910245	A	19990308		
	DE 1999-19959958	A	19991213		
	WO 2000-EP1498	W	20000224		
OS	MARPAT 133:222725				

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:603272 CAPLUS
 DN 129:230732
 TI Preparation of N-(2-heterocyclylphenyl)amides as herbicides
 IN Andree, Roland; Drewes, Mark Wilhelm; Findeisen, Kurt; Kluth, Joachim;
 Linker, Karl-Heinz; Mueller, Klaus-Helmut; Schallner, Otto; Dollinger,
 Markus
 PA Bayer A.-G., Germany
 SO Ger. Offen., 70 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19708928	A1	19980910	DE 1997-19708928	19970305
	CA 2283298	AA	19980911	CA 1998-2283298	19980220
	WO 9839304	A1	19980911	WO 1998-EP972	19980220

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9866226	A1	19980922	AU 1998-66226	19980220
AU 731129	B2	20010322		
EP 973752	A1	20000126	EP 1998-908103	19980220
EP 973752	B1	20050511		
R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL				
BR 9808200	A	20000516	BR 1998-8200	19980220
JP 2001513785	T2	20010904	JP 1998-538103	19980220
MX 9908144	A	20000131	MX 1999-8144	19990903
US 6602826	B1	20030805	US 1999-367476	19990920
US 6686318	B1	20040203	US 2003-420203	20030422
PRAI DE 1997-19708928	A	19970305		
WO 1998-EP972	W	19980220		
US 1999-367476	A3	19990920		
OS MARPAT 129:230732				

L6 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:758682 CAPLUS

DN 123:169279

TI Preparation of cyclohexanediurea derivatives as ACAT inhibitors

IN Yamada, Toshihiro; Nobuhara, Yoichi; Takagi, Ichinari; Furumoto, Shiho; Kobayashi, Kazuhiro; Ikemoto, Kiyohito

PA Nissin Food Products Co., Ltd., Japan

SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9507258	A1	19950316	WO 1994-JP1475	19940907
	W: AU, CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 07082232	A2	19950328	JP 1993-226247	19930910
	JP 3286745	B2	20020527		
	CA 2171295	AA	19950316	CA 1994-2171295	19940907
	AU 9476235	A1	19950327	AU 1994-76235	19940907
	AU 680941	B2	19970814		
	EP 718281	A1	19960626	EP 1994-926366	19940907
	EP 718281	B1	20010627		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 202555	E	20010715	AT 1994-926366	19940907
	US 5733931	A	19980331	US 1996-617828	19960308
PRAI	JP 1993-226247	A	19930910		
	WO 1994-JP1475	W	19940907		
OS	MARPAT 123:169279				

L6 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:648096 CAPLUS

DN 123:55933

TI Preparation of 3-phenylureido-1,4-benzodiazepine selective cholecystokinin-B and/or gastrin receptor antagonists

IN Semple, Graeme; Ryder, Hamish; Szelke, Michael; Satoh, Masato; Ohta, Mitsuaki; Miyata, Keiji; Nishida, Akito

PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Ferring Research Ltd.

SO PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9506041	A1	19950302	WO 1994-GB1858	19940825
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	GB 2282594	A1	19950412	GB 1993-17692	19930825
	AU 9474660	A1	19950321	AU 1994-74660	19940825
PRAI	GB 1993-17692	A	19930825		
	WO 1994-GB1858	W	19940825		
OS	MARPAT 123:55933				

L6 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:531008 CAPLUS

DN 117:131008

TI Amidoxime functions as neighboring groups in cyclodehydrogenation reactions

AU Moehrle, Hans; Lessel, Juergen

CS Inst. Pharm. Chem., Univ. Duesseldorf, Duesseldorf, W-4000/1, Germany

SO Chemische Berichte (1992), 125(8), 1843-9

CODEN: CHBEAM; ISSN: 0009-2940

DT Journal

LA German

OS CASREACT 117:131008

L6 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1978:563531 CAPLUS

DN 89:163531

TI Cyclodehydrogenation of aniline derivatives with aromatic carboxamide or urea functions

AU Moehrle, Hans; Hemmerling, Hans Joerg

CS Inst. Pharm. Chem., Univ. Duesseldorf, Duesseldorf, Fed. Rep. Ger.

SO Archiv der Pharmazie (Weinheim, Germany) (1978), 311(7), 586-94

CODEN: ARPMAS; ISSN: 0365-6233

DT Journal

LA German

OS CASREACT 89:163531

L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:156229 CAPLUS

DN 82:156229

TI Heterocyclic syntheses. XXVIII. ortho-(Dialkylamino)benzenesulfonyl azides, -benzoyl azides, and -benzoyldiazomethanes

AU Martin, John; Meth-Cohn, Otto; Suschitzky, Hans

CS Ramage Lab., Univ. Salford, Salford, UK

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1974), (21), 2451-8

CODEN: JCPRB4; ISSN: 0300-922X


DT Journal

LA English

OS CASREACT 82:156229

=> d hitstr 16

L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
IT 55259-36-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55259-36-4 CAPLUS
CN Urea, N,N'-bis[2-(hexahydro-1H-azepin-1-yl)-5-nitrophenyl]- (9CI) (CA
INDEX NAME)



(FILE 'CAPLUS' ENTERED AT 09:38:59 ON 24 AUG 2006)
L6 16 S L5

FILE 'REGISTRY' ENTERED AT 09:40:41 ON 24 AUG 2006

=> d hitstr 15

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:end

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.32

206.50

FILE 'CAPLUS' ENTERED AT 09:42:12 ON 24 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2006 VOL 145 ISS 9

FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d hitstr 15

L6 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 67829-57-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclodehydrogenation of)

RN 67829-57-6 CAPLUS

CN Urea, [2-(hexahydro-1H-azepin-1-yl)phenyl]- (9CI) (CA INDEX NAME)




IT 67829-58-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 67829-58-7 CAPLUS
CN Urea, [2-(hexahydro-1H-azepin-1-yl)phenyl]-, monoperchlorate (9CI) (CA
INDEX NAME)


CM 1

CRN 67829-57-6
CMF C13 H19 N3 O




CM 2

CRN 7601-90-3
CMF Cl H O4




=> d hitstr 16

L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
IT 55259-36-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55259-36-4 CAPLUS
CN Urea, N,N'-bis[2-(hexahydro-1H-azepin-1-yl)-5-nitrophenyl]- (9CI) (CA
INDEX NAME)



=> d hitstr 14


L6 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
IT 140410-89-5P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and spectra of)
RN 140410-89-5 CAPLUS
CN Urea, N-(1,1-dimethylethyl)-N'-[2-(hexahydro-1H-azepin-1-yl)phenyl]- (9CI)
(CA INDEX NAME)



=> d hitstr 13

L6 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
IT 164343-30-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of 3-phenylureido-1,4-benzodiazepine selective cholecystokinin-B and/or gastrin receptor antagonists)
RN 164343-30-0 CAPLUS
CN Urea, N-[1-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(hexahydro-1H-azepin-1-yl)phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 12

L6 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 166967-92-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).


(preparation of cyclohexanediurea derivs. as ACAT inhibitors)

RN 166967-92-6 CAPLUS


CN Urea, N,N''-[1,4-cyclohexanediylbis(methylene)]bis[N-cyclohexyl-N'-[4-(hexahydro-1H-azepin-1-yl)phenyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




●2 HCl


=> d hitstr 11

L6 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 212903-67-8P 212903-72-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(2-heterocyclylphenyl)amides as herbicides)
 RN 212903-67-8 CAPLUS
 CN Urea, N-[5-chloro-2-(6,7,8,9-tetrahydro-3-oxo-3H-1,2,4-triazolo[4,3-a]azepin-2(5H)-yl)phenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 212903-72-5 CAPLUS
 CN Urea, N-methyl-N'-[2-(6,7,8,9-tetrahydro-3-oxo-3H-1,2,4-triazolo[4,3-a]azepin-2(5H)-yl)phenyl]- (9CI) (CA INDEX NAME)




=> d hitstr 10

L6 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
 IT 292137-30-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thiazolylureas as antivirals)
 RN 292137-30-5 CAPLUS
 CN 5-Thiazolesulfonamide, 2-[[[4-(hexahydro-1H-azepin-1-yl)phenyl]amino]carbonyl]methylamino]-N,N,4-trimethyl- (9CI) (CA INDEX NAME)




=> d hitstr 9

L6 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
IT 359841-52-4
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)
(oxidative hair dyes containing paraphenylenediamine derivs. direct dyes)
RN 359841-52-4 CAPLUS
CN Urea, [2-amino-5-(hexahydro-3-hydroxy-1H-azepin-1-yl)phenyl]- (9CI) (CA
INDEX NAME)




=> d hitstr 8

L6 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
IT 359841-52-4
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)
(oxidative hair dyes comprising substituted paraphenylenediamine
derivs. and polymers)
RN 359841-52-4 CAPLUS
CN Urea, [2-amino-5-(hexahydro-3-hydroxy-1H-azepin-1-yl)phenyl]- (9CI) (CA
INDEX NAME)



=> d hitstr 7

L6 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
IT 359841-52-4
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)
(oxidation dyeing composition for keratinous fibers containing
paraphenylenediamine
derivs. and oxidants)
RN 359841-52-4 CAPLUS
CN Urea, [2-amino-5-(hexahydro-3-hydroxy-1H-azepin-1-yl)phenyl]- (9CI) (CA
INDEX NAME)



=> d hitstr 6

L6 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 359841-52-4

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(oxidation dyeing composition for keratinous fibers comprising paraphenylenediamine derivs. and coupling agents)

RN 359841-52-4 CAPLUS

CN Urea, [2-amino-5-(hexahydro-3-hydroxy-1H-azepin-1-yl)phenyl]- (9CI) (CA INDEX NAME)



=> d hitstr 5

L6 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 359841-52-4

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(oxidative hair dye preparation containing paraphenylenediamine derivs.)

RN 359841-52-4 CAPLUS

CN Urea, [2-amino-5-(hexahydro-3-hydroxy-1H-azepin-1-yl)phenyl]- (9CI) (CA INDEX NAME)



=> d hitstr 4

L6 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 500013-85-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indolylureas and relate compds. for the treatment of obesity and type II diabetes)

RN 500013-85-4 CAPLUS

CN Urea, N-[1-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N'-[4-(hexahydro-1H-azepin-1-yl)phenyl]- (9CI) (CA INDEX NAME)



=> d hitstr 3

L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN


IT 623934-46-3P 623934-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of semicarbazides as inhibitors of blood-coagulation factor Xa and VIIa)


RN 623934-46-3 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(aminomethyl)phenyl]-N-[4-(hexahydro-2-oxo-1H-azepin-1-yl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 623934-47-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(aminomethyl)phenyl]-N-[4-(hexahydro-2-oxo-1H-azepin-1-yl)phenyl]-1-phenyl- (9CI) (CA INDEX NAME)



=> d hitstr 2

L6 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN

IT 870072-15-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of urea containing N-aryl or N-heteroaryl substituted heterocycles

as antagonists of P2Y1 receptor for treating thrombotic conditions)

RN 870072-15-4 CAPLUS

CN Urea, N-[2-(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)phenyl]-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



=> d hitstr 1

'HITSTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
 ENTER DISPLAY FORMAT (BIB):hitstr

L6 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
 IT 877202-75-0P, 1-[4-(Azepan-1-yl)-3-fluorophenyl]-3-(4-chlorophenyl)urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of aryl urea derivs. as CB1 receptor modulators)
 RN 877202-75-0 CAPLUS
 CN Urea, N-(4-chlorophenyl)-N'-[3-fluoro-4-(hexahydro-1H-azepin-1-yl)phenyl]-
 (9CI) (CA INDEX NAME)

